Axumin® (fluciclovine F 18) Imaging Center Location Directory

During this time, we understand that access to Axumin PET/CT scans in hospitals may be challenging in some U.S. locations due to COVID-19, especially for vulnerable patients including those who are immunocompromised. In the Axumin Imaging Center Location Directory, hospitals are noted with the following icon:  

We suggest contacting the imaging centers in your local area to confirm the ability to schedule a PET/CT scan as well as confirm compliance with the Centers for Disease Control and Prevention (CDC) COVID-19 guidelines, as well as any applicable local and state guidelines.

The imaging centers and physicians included in this list are those who have given their consent to be identified. It is not an exhaustive or complete list of all sites that offer imaging services using Axumin. This information is provided as a reference for referring physicians and is not intended to be an endorsement by Blue Earth Diagnostics, Inc. (BED) of the physicians or sites listed, nor is it an endorsement of BED by those sites. It is the responsibility of the referring physician to determine whether Axumin is the right option for their patients and to identify an appropriate referral site if Axumin is not available at their location.

INDICATION

Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

  • Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
  • Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
  • Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
  • Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Axumin full Prescribing Information.

You are now leaving Axumin.com. Do you wish to proceed?

Yes, proceed.
No, take me back to Axumin.com